225.3: Randomized phase 2 trial of felzartamab in humoral transplant rejection.
Katharina A. Mayer(Medical University of Vienna), Georg A. Böhmig(Medical University of Vienna), Nicolas Kozakowski(Medical University of Vienna), Bilgin Osmanodja(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), Aylin Akifova(Charité - Universitätsmedizin Berlin), Eva Schrezenmeier(Leibniz Association), Hannes Vietzen(Medical University of Vienna), Johannes Kläger(Medical University of Vienna), Jaideep S. Dudani(Medical University of Vienna), Klemens Budde(Charité - Universitätsmedizin Berlin), Heinz Regele(University of Vienna), Philip F. Halloran(University of Alberta), Konstantin Doberer(Medical University of Vienna), Farsad Eskandary(Medical University of Vienna), Bernd Jilma(Medical University of Vienna), Fabian Halleck(Charité - Universitätsmedizin Berlin), Martina Schatzl(Medical University of Vienna), Elisabeth Puchhammer-Stöckl(Medical University of Vienna), Julia Beck(Medical University of Vienna), Ekkehard Schütz(Medical University of Vienna), Kerstin Amann(Medical University of Vienna), Alexander Kainz(Medical University of Vienna), Uptdal D Patel, Matthias Diebold(University of Basel)
Cited by 0
Related Papers
The Banff 97 working classification of renal allograft pathology
|Kidney International|1999|3.1k
Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions
|American Journal of Transplantation|2008|1.9k
Understanding the Causes of Kidney Transplant Failure: The Dominant Role of Antibody-Mediated Rejection and Nonadherence
|American Journal of Transplantation|2011|1.6k
International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology
|Kidney International|1993|1.5k
Antibody-Mediated Rejection Criteria - an Addition to the Banff ’97 Classification of Renal Allograft Rejection
|American Journal of Transplantation|2003|1.1k